Analysts at Royal Bank Of Canada assumed coverage on shares of Bruker (NASDAQ:BRKR – Get Free Report) in a note issued to investors on Friday, Briefing.com reports. The brokerage set a “sector perform” rating and a $66.00 price target on the medical research company’s stock. Royal Bank Of Canada‘s price target points to a potential upside of 6.28% from the company’s current price.
Several other research firms also recently commented on BRKR. UBS Group initiated coverage on Bruker in a report on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price objective on the stock. TD Cowen raised their price objective on shares of Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. Barclays boosted their price target on shares of Bruker from $58.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Finally, JPMorgan Chase & Co. cut shares of Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 price objective for the company. in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $61.00.
View Our Latest Stock Report on BRKR
Bruker Trading Down 1.8%
NASDAQ BRKR opened at $62.10 on Friday. Bruker has a 1-year low of $32.37 and a 1-year high of $68.98. The firm has a market cap of $9.48 billion, a PE ratio of -56.45, a price-to-earnings-growth ratio of 1.84 and a beta of 1.26. The company has a current ratio of 1.84, a quick ratio of 0.90 and a debt-to-equity ratio of 0.74. The stock has a 50-day moving average of $59.93 and a 200-day moving average of $51.25.
Bruker (NASDAQ:BRKR – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.14. Bruker had a negative net margin of 3.82% and a positive return on equity of 13.76%. The company had revenue of $874.00 million during the quarter, compared to analyst estimates of $865.16 million. During the same period last year, the business earned $0.45 EPS. Bruker’s quarterly revenue was up 1.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Bruker will post 2.13 EPS for the current year.
Insider Buying and Selling
In other news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares in the company, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 27.20% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC increased its position in shares of Bruker by 6.0% during the 3rd quarter. Kestra Advisory Services LLC now owns 4,947 shares of the medical research company’s stock valued at $320,000 after purchasing an additional 282 shares during the period. Coastal Bridge Advisors LLC acquired a new position in shares of Bruker during the 3rd quarter worth $254,000. Integrated Wealth Concepts LLC boosted its stake in shares of Bruker by 14.9% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 8,491 shares of the medical research company’s stock worth $550,000 after acquiring an additional 1,101 shares in the last quarter. Allworth Financial LP boosted its holdings in shares of Bruker by 40.3% during the 3rd quarter. Allworth Financial LP now owns 5,434 shares of the medical research company’s stock worth $352,000 after buying an additional 1,561 shares during the period. Finally, Quantitative Investment Management LLC acquired a new position in shares of Bruker during the third quarter valued at about $427,000. 79.52% of the stock is currently owned by institutional investors.
Bruker Company Profile
Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company’s offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.
Featured Articles
- Five stocks we like better than Bruker
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
